Gelaspan vs standard fluids for sepsis with belly infection
Part of Infections clinical trials.
This trial tests whether a fluid called Gelaspan (a gelatin-based IV fluid) is better for treating sepsis patients who need emergency abdominal surgery than standard crystalloid fluids. It checks if you have a belly infection and high lactate levels, and you must not have serious heart, lung, or kidney problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have sepsis caused by an infection in your belly and need emergency surgery to control it
- Your blood lactate level is higher than 2 mmol/L (within the last 6 hours)
- You have not received colloid fluids (like gelatin) in the past 24 hours
- You do not have certain heart or lung conditions (like atrial fibrillation, congestive heart failure, or severe ARDS)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a type of diabetes medicine (SGLT2 inhibitors) can help adults with sepsis, a life-threatening response to infection. If you have new-onset sepsis and can take oral medicine, you may be eligible.
This trial compares two common IV fluids (normal saline and Ringer's lactate) to see which one works better for initial hydration in people with sepsis in the emergency department. It aims to find the safest and most effective way to give fluids early in sepsis treatment.
This Phase 2 study tests whether Pentaglobin®, a blood-product made from immune proteins, helps critically ill people with severe abdominal infection (peritonitis) after the infection source is surgically cleaned up. It targets patients with signs of strong inflammation and severe illness.
This trial tests a new treatment to protect and repair the layer of cells lining your blood vessels (glycocalyx) during sepsis. It aims to improve recovery from severe infections.
This study tests whether giving an early antibiotic (meropenem) based on a new blood test (PSP) can prevent serious infections (sepsis) in people who come to the emergency department with signs of infection. The goal is to find out if this approach helps them get better faster and avoid more severe illness.
This study tests whether using a non-invasive monitor to guide fluid and medication decisions helps people with sepsis recover better than standard care. It aims to improve blood flow and organ function without extra needles or procedures.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.